How much funding has Neurelis raised?

Neurelis has raised $314.0M in total funding, most recently a Series D round.

Who are Neurelis's investors?

Neurelis's investors include HBM Healthcare Investments, OrbiMed, Cormorant, LYZZ Capital.

Where is Neurelis headquartered?

Neurelis is headquartered in San Diego, California, United States.

What industry is Neurelis in?

Neurelis operates in Biotech, Healthcare.

Neurelis

Neurelis®: Helping More People Define Their Neu Normal

San Diego, United States · Founded 2007 · $314.0M raised

Biotech

Healthcare

Headquarters: San Diego, California
Employees: 51–200
Founded: 2007
Business Model: B2B

Website: neurelis.com
Total Funding: $314.0M
Last Round: $114.0M Series DJun 2023
Rounds: 4

About

Neurelis is a commercial-stage neuroscience company founded in 2007 in San Diego, focused on developing and commercializing therapeutics for epilepsy and central nervous system disorders. Its flagship product, approved by the FDA, leverages proprietary Intravail absorption technology and has achieved coverage of over 285 million insured US lives.

Summary

Neurelis is a Biotech company based in San Diego, United States, founded in 2007. It has raised $314.0M in total across 4 rounds, most recently a $114.0M Series D round in Jun 2023. Investors include HBM Healthcare Investments, OrbiMed and Cormorant.

LinkedIn X (Twitter)